相关实验视频
Updated: Jun 30, 2025

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.7K
Abca7V1613M变种减少了Aβ生成,斑块负载和神经元损伤
Claire A Butler1,2, Adrian Mendoza Arvilla2, Giedre Milinkeviciute2
1Department of Neurobiology and Behavior, University of California, Irvine, California, USA.
概括
在小鼠中的ABCA7 V1613M变体显示出改变的微质功能和脂质代谢. 这种阿尔茨海默氏症风险变体可能通过减少粉样β病理和相关损伤来提供保护作用.
科学领域:
- 遗传学和分子生物学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- ATP结合盒载体A7 (ABCA7) 是一种关键基因,与晚发性阿尔茨海默病 (LOAD) 风险相关.
- 在ABCA7中失去功能的突变增加了对LOAD的敏感性.
- 人类的特定V1599M变体及其小鼠同类V1613M正在研究它们对阿尔茨海默氏症病理学的影响.
研究的目的:
- 在小鼠模型中研究Abca7 V1613M变异的功能后果.
- 确定这种变体对微质功能,脂质代谢和粉样β (Aβ) 病理学的影响.
- 评估Abca7 V1613M变体对与阿尔茨海默氏症相关的神经退行症的潜在保护作用.
主要方法:
- 使用CRISPR-Cas9基因编辑,在小鼠中创建了Abca7 V1613M变体.
- 对Abca7 V1613M小鼠的综合性表征,包括微质对脂多糖的反应,细胞容量和脂质概况.
- 杂交Abca7 V1613M小鼠与5xFAD转基因小鼠,以评估对Aβ斑块负担,Aβ和相关神经病理学的影响.
主要成果:
- Abca7 V1613M微质表现出改变的基因表达和增强的细胞化.
- 同性卵性Abca7 V1613M小鼠显示胆固醇升高和大脑脂质组成的改变.
- 在5xFAD小鼠中,Abca7 V1613M变体显著减少了粉样质斑块,Aβ,炎症,质症和神经元损伤.
结论:
- 对于Abca7 V1613M变体的同胞性影响小鼠的微质功能,脂质代谢和Aβ病理.
- 这种V1613M变异可能代表一种功能获取突变.
- 这种变体显示出对阿尔茨海默病相关病理的潜在保护作用,需要进一步调查.
相关概念视频
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186

